AWA
ALNY icon

Aaron Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Aaron Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
1,153
+424
+58% +$128K 0.02% 536
2026
Q1 		$241K Sell
729
-203
-22% -$69.1K 0.01% 621
2025
Q4 		$371K Sell
932
-177
-16% -$78.3K 0.02% 517
2025
Q3 		$506K Buy
+1,109
New +$452K 0.03% 409

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aaron Wealth Advisors's ALNY Position: Q2 2026 in Review

Aaron Wealth Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 58% in Q2 2026, buying an estimated $128K and bringing the position to 1,153 shares worth $347K. The position accounts for 0.02% of the portfolio, ranked #536.

Aaron Wealth Advisors first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $506K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Aaron Wealth Advisors held 1,153 shares of Alnylam Pharmaceuticals worth $347K as of Q2 2026.
  • Aaron Wealth Advisors bought 424 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $128K.
  • Alnylam Pharmaceuticals made up 0.02% of Aaron Wealth Advisors's portfolio in Q2 2026, its #536 holding.
  • Aaron Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Aaron Wealth Advisors's Alnylam Pharmaceuticals position peaked at $506K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Aaron Wealth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.